Date: 2015-10-27
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Ares Allergy Holdings (UK) now Stallergenes Greer (UK)
Therapeutic area: Allergic diseases
Type agreement: name change
Action mechanism:
Disease:
Details: * On October 27, 2015, Ares Allergy Holdings announced that it is changing its name to Stallergenes Greer plc. This decision was approved by the shareholders during the Extraordinary General Meeting held in Paris. The name change is effective from 27 October 2015 and will be progressively implemented globally. Headquartered in London (UK), Stallergenes Greer plc is a global company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). Stallergenes Greer plc had combined sales in 2014 of €312.5 million ($ 344 million), EBITDA of €89.2 million (USD 98.3 million) and over 1,400 employees worldwide. The Company’s business model, which is focused on select strategic research programs, manufacturing, development, marketing and M&A, will allow the Company to grow globally, in the expanding allergy immunotherapy market. The company will provide an update on its R&D pipeline in Q2 2016.
Financial terms:
Latest news:
